Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer. (PubMed, Int J Mol Sci) - Sep 16, 2026 - "Carboplatin/paclitaxel (CP) chemotherapy is the cornerstone of therapy for advanced stage ovarian cancer (OC)...Ixabepilone ± bevacizumab (IB) is a combination recently added to NCCN guidelines for the treatment of platinum-resistant OC...Alterations in genes associated with tumor growth/progression correlated with resistance to CP regimen and may represent novel "druggable" candidate biomarkers for the targeted treatment of CP/IB-resistant patients. Further validation in independent cohorts and preclinical experiments in CP/IB-resistant models are warranted to establish the clinical utility of these findings."
Biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • ACVR2A • ATG5 • LRRK2 • MAP3K7 • RSPO3 • SDHA
|
|
Alessandro D Santin; Ammal Abbasi; Cem Demirkiran; Kevin Y Yang; Ludmil B Alexandrov; Michelle Greenman; Namrata Sethi; Orazio De Tommasi; Sarah Ottum; Stefania Bellone; Tobias M P Hartwich; Victoria Ettorre
|